Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 341 Ovarian Neoplasms 177 Lung Neoplasms 171 Breast Neoplasms 118 Fallopian Tube Neoplasms 87 Neoplasms 79 Carcinoma, Ovarian Epithelial 69 Squamous Cell Carcinoma of Head and Neck 51 Small Cell Lung Carcinoma 49 Triple Negative Breast Neoplasms 41 Adenocarcinoma of Lung 41 Head and Neck Neoplasms 40 Neoplasm Metastasis 37 Neuroblastoma 34 Central Nervous System Neoplasms 33 Endometrial Neoplasms 28 Esophageal Neoplasms 27 Carcinoma 27 Brain Neoplasms 27 Lymphoma 26 Recurrence 25 Parkinson Disease 4, Autosomal Dominant Lewy Body 25 Lymphoma, Large B-Cell, Diffuse 25 Urinary Bladder Neoplasms 24 Adenocarcinoma, Bronchiolo-Alveolar 23 Testicular Neoplasms 22 Astrocytoma 22 Melanoma 19 Uterine Cervical Neoplasms 18 Prostatic Neoplasms 18

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Carboplatin × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡